Medicare AdvantageCoverageMedium impact
MA08.138e, Tafasitamab-cxix (Monjuvi®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
May 27, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.138e for Tafasitamab-cxix (Monjuvi®) has been reissued with updates effective May 27, 2026. This is a pharmacy policy update that may affect coverage criteria or prior authorization requirements for this oncology drug used to treat certain lymphomas.
Action Required
By May 27, 2026: Billing and clinical teams should review the updated policy for Tafasitamab-cxix (Monjuvi®) at the provided URL to understand any changes to coverage criteria, prior authorization requirements, or documentation needs. Update prior authorization workflows and patient eligibility verification processes accordingly for Medicare Advantage patients requiring this oncology medication.